NCT01514721View on ClinicalTrials.gov

Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination) From Prior Therapy

PHASE4TerminatedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Glaucoma
Interventions
DRUG

Travoprost/Timolol Maleate BAK-Free Fixed Combination

Commercially marketed Travoprost/Timolol BAK-free ophthalmic solution indicated for the treatment of patients with open angle glaucoma (OAG) or ocular hypertension (OH).

Trial Locations (1)

Unknown

Alcon Investigational Site, São Paulo

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY

NCT01514721 - Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination) From Prior Therapy | Biotech Hunter | Biotech Hunter